Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allurion TechnologiesALURD 11 5-Year Yield-on-Cost % is 0.00 as of Aug. 10, 2026. GuruFocus rates ALURD with a GF Score™ of 11/100 and a GF Value™ of $10.41 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 318 Medical Devices & Instruments companies, Allurion Technologies ranks worse than 314465.09% on this metric.
Allurion Technologies's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Allurion Technologies's 5-Year Yield-on-Cost % or its related term are showing as below:
ALURD's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.355 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Allurion Technologies 5-Year Yield-on-Cost % Related Terms
ALURD vs ITOC, USAQ, WOK: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Allurion Technologies's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allurion Technologies 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Allurion Technologies's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Allurion Technologies (ALURD) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 10, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Allurion Technologies and its competitors. According to the industry distribution chart, Allurion Technologies ranks #999999 out of 318 companies in the Medical Devices & Instruments industry.
Is Allurion Technologies' 5-Year Yield-on-Cost % too high?
Allurion Technologies' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Allurion Technologies ranks #999999 out of 318 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Allurion Technologies has a GF Score™ of 11/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Allurion Technologies' 5-Year Yield-on-Cost % compare to ITOC and USAQ?
According to the Medical Devices & Instruments industry distribution chart, Allurion Technologies ranks #999999 out of 318 companies for 5-Year Yield-on-Cost %. This places Allurion Technologies in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.36, based on 318 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Allurion Technologies and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allurion Technologies's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allurion Technologies stock overvalued right now?
Based on GuruFocus' analysis, Allurion Technologies (ALURD) is currently considered Possible Value Trap. The stock's GF Value™ is $10.41, compared to a current price of $4.30 — trading 58.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Allurion Technologies' overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Allurion Technologies (ALURD), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allurion Technologies (ALURD) Overvalued in 2026?
Based on GuruFocus' analysis, Allurion Technologies stock appears to be undervalued.
The current stock price of $4.30 is trading 58.7% below its estimated GF Value™ of $10.41.
GuruFocus considers Allurion Technologies to be Possible Value Trap.
Key valuation signals for ALURD:
5-Year Yield-on-Cost %: 0.00
GF Value™: $10.41 vs. price of $4.30 (58.7% below fair value)
No single metric tells the full story. See the ALURD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
11GF Score
Get the complete analysis for ALURD
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALURD has been successfully added to your 
